Access Erbitux
Trademark details
Access Erbitux® is a registered trademark used for Assistance To Others In Respect of Health Insurance Coverage For Pharmaceuticals, Namely, Administering Pharmacy Reimbursement Programs and Services Charitable Assistance To Others In Respect of Health Insurance Coverage For Pharmaceuticals, Namely, Patient Assistance Program To Provide Drugs Free of Charge To Low-Income Patients Without Prescription Drug Coverage and owned by ImClone Systems Incorporated. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Assistance To Others In Respect of Health Insurance Coverage For Pharmaceuticals, Namely, Administering Pharmacy Reimbursement Programs and Services Charitable Assistance To Others In Respect of Health Insurance Coverage For Pharmaceuticals, Namely, Patient Assistance Program To Provide Drugs Free of Charge To Low-Income Patients Without Prescription Drug Coverage |
| Serial Number: | 76648586 |
| Filing Date: | Oct 17, 2005 |
|
Last Applicant(s)/ Owner(s) of Record | ImClone Systems Incorporated180 Varick Street, 6th Floor |
| Related Products: | Advertising and Business, Medical services; Veterinary services; Hygienic and beauty care for humans or animals |
Web Sites
powered by 
Total : 192,000 View more »
Bristol-Myers Squibb Destination Access - ERBITUX Patient ...
Bristol-Myers Squibb Destination Access - ERBITUX Patient Assistance Program Bristol-Myers Squibb Company
Destination Access: Reimbursement Assistance and Prescription ...
Welcome to Destination Access, your comprehensive resource for Bristol-Myers Squibb patient reimbursement assistance.
ERBITUX (cetuximab) Reimbursement and Support | Head and Neck Cancer
ERBITUX ® (cetuximab) Reimbursement and Support Destination Access™ Destination Access™ is a program developed by Bristol-Myers Squibb to aid patients and ...
Destination Access™ | Reimbursement Support
IMPORTANT SAFETY INFORMATION | Destination Access is a comprehensive resource provided by Bristol-Myers Squibb to aid with reimbursement for ERBITUX (cetuximab)
